Teva names CEOs for Japanese, Korean units

Ichiro Kikushige will become CEO Teva Seiyaku and Yoo Suk Hong will become the first CEO of Teva-Handok in Korea.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has named the CEOs of its Japanese and Korean units. Ichiro Kikushige will become CEO Teva Seiyaku Ltd. in Japan, effective on May 15, succeeding Makoto Shimada, who is retiring after 40 in Japan's pharmaceutical industry.

Teva also announced that Yoo Suk Hong will become the first CEO of Teva-Handok, the Korean joint venture established in February 2013 between Teva and Handok Pharmaceuticals Ltd. (KRX: 2390). Teva-Handok will launch its first products in September.

Teva Japan and Teva South Korea CEO Prof. Itzhak Krinsky said, “As an effective leader with more than 30 years of experience in the pharmaceutical industry, Mr. Kikushige is well-qualified to assume this important role within Teva in Japan."

Regarding Yoo Suk Hong, Krinsky said, “As we prepare to officially launch Teva-Handok, we are very pleased to welcome him as our CEO. “With his deep international experience coupled with his keen understanding of the Korean market, Yoo Suk will help us realize our goal of bringing high-quality and affordable medicines to patients in Korea."

Published by Globes [online], Israel business news - - on April 8, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018